Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sangamo Therapeutics (SGMO) Revenue (2016 - 2025)

Sangamo Therapeutics has reported Revenue over the past 16 years, most recently at $14.2 million for Q4 2025.

  • Quarterly results put Revenue at $14.2 million for Q4 2025, up 118.89% from a year ago — trailing twelve months through Dec 2025 was $39.6 million (down 30.3% YoY), and the annual figure for FY2025 was $39.6 million, down 31.57%.
  • Revenue for Q4 2025 was $14.2 million at Sangamo Therapeutics, up from $581000.0 in the prior quarter.
  • Over the last five years, Revenue for SGMO hit a ceiling of $158.0 million in Q1 2023 and a floor of $356000.0 in Q2 2024.
  • Median Revenue over the past 5 years was $18.3 million (2025), compared with a mean of $24.6 million.
  • Biggest five-year swings in Revenue: crashed 99.7% in 2024 and later surged 5042.13% in 2025.
  • Sangamo Therapeutics' Revenue stood at $28.6 million in 2021, then fell by 4.67% to $27.2 million in 2022, then crashed by 92.5% to $2.0 million in 2023, then soared by 218.32% to $6.5 million in 2024, then skyrocketed by 118.89% to $14.2 million in 2025.
  • The last three reported values for Revenue were $14.2 million (Q4 2025), $581000.0 (Q3 2025), and $18.3 million (Q2 2025) per Business Quant data.